Shazhiside methyl ester gentiobioside



Compound IDCDAMM01943
Common nameShazhiside methyl ester gentiobioside
IUPAC namemethyl 5,7-dihydroxy-7-methyl-1-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-4a,5,6,7a-tetrahydro-1H-cyclopenta[c]pyran-4-carboxylate
Molecular formulaC23H36O16

Experimental data

Retention time28.23
Adduct[M+H]+
Actual mz569.212
Theoretical mz569.207
Error8.12
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.2589

Identifiers and class information

Inchi keyFFKQCCZXUVIIPM-JHVZDRKZNA-N
SmilesO=C(OC)C1=COC(OC2OC(COC3OC(CO)C(O)C(O)C3O)C(O)C(O)C2O)C4C1C(O)CC4(O)C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)10
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)16
Number of reactive functional groups (#rtvFG)4
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)568.528
Computed dipole moment(dipole)8.982
Total solvent accessible surface area (SASA)808.019
Hydrophobic component of SASA (FOSA)400.381
Hydrophilic component of SASA (FISA)380.284
Pie component of the SASA (PISA)27.354
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1550.31
Number of hydrogen bond donors (donorHB)9
Number of hydrogen bond acceptors (accptHB)24.85
Free energy of solvation of dipole (dip^2/V)0.0520412
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0922627
Globularity descriptor (glob)0.801718
Predicted polarizability in cubic angstroms (QPpolrz)45.877
Predicted hexadecane/gas partition coefficient (QPlogPC16)17.526
Predicted octanol/gas partition coefficient (QPlogPoct)42.994
Predicted water/gas partition coefficient (QPlogPw)38.565
Predicted octanol/water partition coefficient (QPlogPo/w)-3.899
Predicted aqueous solubility (QPlogS)-1.521
Conformation-independent predicted aqueous solubility (CIQPlogS)-1.206
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.871
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)2.453
Predicted brain/blood partition coefficient (QPlogBB)-4.345
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.746
Predicted skin permeability, log Kp (QPlogKp)-6.896
PM3 calculated ionization potential (IP(ev))9.897
PM3 calculated electron affinity (EA(eV))0.231
Number of likely metabolic reactions (#metab)10
Prediction of binding to human serum albumin (QPlogKhsa)-1.869
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)263.479
Number of nitrogen and oxygen atoms (#NandO)16
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
Q16790CA9Carbonic anhydrase IXT64567SEA
Q9ULX7CA14Carbonic anhydrase XIVT31992SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
P20916MAGMyelin-associated glycoprotein (by homology)T95286SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T64567DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q16790CA9
T31992DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q9ULX7CA14
T31992DI0204Inborn metabolism deficiency[ICD-11: 5C50-5C59]Q9ULX7CA14
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T95286DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P20916MAG
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP

Copyright © 2025